Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched
This article was originally published in The Pink Sheet Daily
Executive Summary
After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.
You may also be interested in...
Keeping Track: So. Much. News.
The latest drug development news and highlights from our US FDA Performance Tracker.
Basilea Plans European Ceftobiprole Launches In Second-Quarter 2014
The broad-spectrum cephalosporin, the first in a potential portfolio of hospital products for severe infections from the Swiss company, is nearing the market in the U.K. and Scandinavia.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.